TBPH

Theravance Biopharma, Inc. is a biotechnology company in the healthcare sector with a market capitalization of $933.39M. The company operates at a relatively small scale, employing 97 individuals and generating revenue of $80.33M (TTM). In its industry, Theravance Biopharma joins other companies that are focused on developing innovative treatments for various diseases. The company's financial health is characterized by low profitability margins, with gross margin standing at 50.8% and operating margin at -32.3%. However, the net income (TTM) is substantial at $29.34M. The balance sheet shows a relatively high cash position of $329.68M, which contrasts with a significant debt of $44.59M. Return on Equity (ROE) stands at 14.0%, and Return on Assets (ROA) is -5.3%. The current ratio is notably high at 9.48. The company's valuation context reveals a P/E Ratio (TTM) of 31.76, indicating that investors are willing to pay a premium for the company's shares. The forward P/E stands at 10.90, suggesting some optimism about future earnings growth. Revenue Growth (YoY) is notable at 18.5%, but Earnings Growth (YoY) is N/A due to the lack of available data.